Metomotyl 2.5 mg/ml solution for injection for cats and dogs

Authorised

- Metoclopramide hydrochloride

Product identification

Medicine name:
Metomotyl 2.5 mg/ml solution for injection for cats and dogs

Active substance:
Metoclopramide hydrochloride

Target species:
Dog
Cat

Route of administration:
Intramuscular use
Subcutaneous use

Product details

Active substance and strength:
Metoclopramide hydrochloride
2.50 milligram(s) / 1.00 millilitre(s)

Pharmaceutical form:

Solution for injection

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QA03FA01

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

Authorisation status:
Valid

Authorised in:
Ireland

Package description:
Clear colourless type I glass vial. Red chlorobutyl 20 mm stopper. Aluminium 20 mm cap. Cardboard box containing 1 vial of 50 ml.
Clear colourless type I glass vial. Red chlorobutyl 20 mm stopper. Aluminium 20 mm cap. Cardboard box containing 1 vial of 5 ml.
Clear colourless type I glass vial. Red chlorobutyl 20 mm stopper. Aluminium 20 mm cap. Cardboard box containing 1 vial of 10 ml.
Clear colourless type I glass vial. Red chlorobutyl 20 mm stopper. Aluminium 20 mm cap. Cardboard box containing 1 vial of 25 ml.
Clear colourless type I glass vial. Red chlorobutyl 20 mm stopper. Aluminium 20 mm cap. Cardboard box containing 1 vial of 20 ml.
Clear colourless type I glass vial. Red chlorobutyl 20 mm stopper. Aluminium 20 mm cap. Cardboard box containing 1 vial of 30 ml.

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Hybrid application (Article 13(3) of Directive No 2001/82/EC)

Marketing authorisation holder:
Le Vet. Beheer B.V.

Marketing authorisation date:
12/09/2014

Manufacturing sites for batch release:
Produlab Pharma B.V.

Responsible authority:
Health Products Regulatory Authority

Authorisation number:
VPA10475/009/001

Date of authorisation status change:
12/09/2014

Reference member state:
Netherlands

Procedure number:
NL/V/0182/001

Concerned member states:
Austria Belgium Czechia Denmark Estonia Finland Germany Greece Hungary Iceland Ireland Italy Latvia Lithuania Luxembourg Norway Poland Portugal Romania Slovakia Spain Sweden United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet